Fritextsökning
Innehållstyper
-
Are you ready for EMC 2024?
Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...
-
New moves around Nykode's management – withdrawal of resignations
Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.
-
Several departures at the top at Nykode
Members of both the management and the board are leaving the Norwegian biotech company Nykode.
-
Novartis storsatsar på RNA-terapier – köper miljardbolag
Novartis förvärvar amerikanska Avidity Biosciences för 12 miljarder dollar, motsvarande 113 miljarder kronor. Köpet stärker bolagets position inom sällsynta mus...
-
Abbvie ryktas överväga miljardförvärv inom mental hälsa
Läkemedelsbolaget Abbvie uppges föra diskussioner om att förvärva Gilgamesh Pharmaceuticals, ett bolag inom mental hälsa, i en affär som ska ligga på omkring en miljard dollar.
-
Major advances in IVF labs in the last few decades
Since the introduction of in vitro fertilisation several decades ago, many developments have been made in the field, and the main part of that development has t...
-
Marie Gårdmark: ”Interchangeable biological medicines – soon in a pharmacy near you?”
”Generic competition is an effective way to push down drug prices, but it has not worked equally well for biosimilars. Biosimilars require more time to gain mar...
-
From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”
A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...
-
ZEISS continues to drive digital era forward in ophthalmology
2 million digitally planned cataract cases in the U.S. alone.
-
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
-
Novo Nordisk to invest billions in new quality control lab
Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.
-
SupraCube - In life Science
restricted. We now present the SupraCube, the first concept in which the superconductor unit can be separated from the electrical cooler and can operate autonom...
-
GU Ventures AB
-
LINK Medical recruits Swedish CEO
The Norwegian Contract Research Organization LINK Medical has recruited Anders Göransson as the new CEO.
-
Basics of Confocal Laser Scanning Microscopy
Learn about the principle of confocal fluorescence microscopy.
-
Superconductor technology: Contactless working in the laboratory of the future
Automated filling and weighing of freeze-dry containers in the cleanroom with SupraMotion from Festo
-
Lucy Robertshaw: Artificial intelligence – is this really going to transform a patient’s life?
In a column Lucy Robertshaw reflects on how AI and new regulations will affect healthcare, innovation and the lives of future patients.
-
MedVasc and Scientific Solutions join forces to streamline FDA 510(k) regulatory process
MedVasc, an exciting MedTech startup company, and Scientific Solutions, a renowned consulting firm within Life Science, are pleased to announce a strategic part...
-
The race between new alzheimer’s drugs Kisunla and Leqembi heats up
Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...
-
“We need to build flexible operating theatres”
Flexible operating theatres, micro-sensors on surgeons to monitor their well-being and 3D images projected onto organs to be operated on. These are a few ideas ...
-
Introduction of ZEISS Imaging Systems for Super-Resolution
Webinar recording about the ZEISS Lattice SIM technology.
-
Allogene discontinues investigational antibody following patient death
U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...
-
Takeover bid is being completed – Japanese company acquires Calliditas
Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...